EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia

Leukemia

Volumn 27, Issue 1, 2013, Pages 56-65

  Konantz, M ^a   Andre M C ^b,c   Ebinger, M ^b   Grauer, M ^a   Wang, H ^a   Grzywna, S ^a   Rothfuss, O C ^b   Lehle, S ^b   Kustikova, O S ^d   Salih, H R ^a   Handgretinger, R ^b   Fend, F ^a   Baum, C ^d   Kanz, L ^a   Quintanilla Martinez, L ^a   Schulze Osthoff, K ^b   Essmann, F ^b   Lengerke, C ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

acute lymphoblastic leukemia; ALL; apoptosis; EVI 1; NSG mice

Indexed keywords

CASPASE 3; CASPASE 7; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DEATH RECEPTOR 4; ECOTROPIC VIRAL INTEGRATION SITE 1 PROTEIN; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN NOXA; PUMA PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; ZINC FINGER PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ADULT; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL CYCLE; CELL PROLIFERATION; CHILD; DNA-BINDING PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENES; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84873571500     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.211     Document Type: Article

References (60)

1. Mucenski ML, Taylor BA, Ihle JN, Hartley JW, Morse III HCJenkins NA et al. Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol 1988; 8: 301-308.
2. Ogawa S, Kurokawa M, Tanaka T, Mitani K, Inazawa J, Hangaishi A et al. Structurally altered Evi-1 protein generated in the 3q21q26 syndrome. Oncogene 1996; 13: 183-191.
3. Suzukawa K, Parganas E, Gajjar A, Abe T, Takahashi S, Tani K et al. Identification of a breakpoint cluster region 30 of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 1994; 84: 2681-2688.
4. Buonamici S, Li D, Chi Y, Zhao R, Wang X, Brace L et al. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest 2004; 114: 713-719.
5. Jin G, Yamazaki Y, Takuwa M, Takahara T, Kaneko K, Kuwata T et al. Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood 2007; 109: 3998-4005.
6. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003; 101: 837-845.
7. Groschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 2010; 28: 2101-2107.
8. Daghistani M, Marin D, Khorashad JS, Wang L, May PC, Paliompeis C et al. EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. Blood 2010; 116: 6014-6017.
9. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350: 1617-1628.
10. Hirai H. The transcription factor Evi-1. Int J Biochem Cell Biol 1999; 31: 1367-1371.
11. Wieser R. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 2007; 396: 346-357.
12. Hoyt PR, Bartholomew C, Davis AJ, Yutzey K, Gamer LW, Potter SS et al. The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development. Mech Dev 1997; 65: 55-70.
13. Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S et al. Evi-1 Is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008; 3: 207-220.
14. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A et al. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 2005; 24: 1976-1987.
15. Gerhardt TM, Schmahl GE, Flotho C, Rath AV, Niemeyer CM. Expression of the Evi-1 gene in haemopoietic cells of children with juvenile myelomonocytic leukaemia and normal donors. Br J Haematol 1997; 99: 882-887.
16. Privitera E, Longoni D, Brambillasca F, Biondi A. EVI-1 gene expression in myeloid clonogenic cells from juvenile myelomonocytic leukemia (JMML). Leukemia 1997; 11: 2045-2048.
17. Delwel R, Funabiki T, Kreider BL, Morishita K, Ihle JN. Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol 1993; 13: 4291-4300.
18. Perkins AS, Fishel R, Jenkins NA, Copeland NG. Evi-1 a murine zinc finger protooncogene, encodes a sequence-specific DNA-binding protein. Mol Cell Biol 1991; 11: 2665-2674.
19. Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood 2001; 97: 2815-2822.
20. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 1998; 394: 92-96.
21. Cattaneo F, Nucifora G. EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression. J Cell Biochem 2008; 105: 344-352.
22. Spensberger D, Delwel R. A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a. FEBS Lett 2008; 582: 2761-2767.
23. Vinatzer U, Taplick J, Seiser C, Fonatsch C, Wieser R. The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase. Br J Haematol 2001; 114: 566-573.
24. Goyama S, Nitta E, Yoshino T, Kako S, Watanabe-Okochi N, Shimabe M et al. EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. Leukemia 2010; 24: 81-88.
25. Poppe B, Dastugue N, Vandesompele J, Cauwelier B, De Smet B, Yigit N et al. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes Cancer 2006; 45: 349-356.
26. De Weer A, Poppe B, Cauwelier B, Van Roy N, Dastugue N, Hagemeijer A et al. Screening for EVI1: ectopic expression absent in T-cell acute lymphoblastic leukemia patients and cell lines. Cancer Genet Cytogenet 2006; 171: 79-80.
27. Andersson A, Ritz C, Lindgren D, Eden P, Lassen C, Heldrup J et al. Microarraybased classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007; 21: 1198-1203.
28. Cario G, Stanulla M, Fine BM, Teuffel O, Neuhoff NV, Schrauder A et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 2005; 105: 821-826.
29. Gunnarsson R, Isaksson A, Mansouri M, Goransson H, Jansson M, Cahill N et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia 2010; 24: 211-215.
30. Riedt T, Ebinger M, Salih HR, Tomiuk J, Handgretinger R, Kanz L et al. Aberrant expression of the homeobox gene CDX2 in pediatric acute lymphoblastic leukemia. Blood 2009; 113: 4049-4051.
31. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R Moricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214.
32. Anastasov N, Klier M, Koch I, Angermeier D, Hofler H, Fend F et al. Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer. J Hematop 2009; 2: 9-19.
33. Maetzig T, Brugman MH, Bartels S, Heinz N, Kustikova OS, Modlich U et al. Polyclonal fluctuation of lentiviral vector-transduced and expanded murine hematopoietic stem cells. Blood 2011; 117: 3053-3064.
34. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-279.
35. Kunder S, Calzada-Wack J, Holzlwimmer G, Muller J, Kloss C, Howat W et al. A comprehensive antibody panel for immunohistochemical analysis of formalinfixed, paraffin-embedded hematopoietic neoplasms of mice: analysis of mouse specific and human antibodies cross-reactive with murine tissue. Toxicol Pathol 2007; 35: 366-375.
36. Barjesteh van Waalwijk van Doorn-Kh S, Erpelinck C, Löwenberg B, Delwal R. Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia. Exp Hematol 2003; 31: 1066-1072.
37. Vinatzer U, Mannhalter C, Mitterbauer M, Gruener H, Greinix H, Schmidt HH et al. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia. Genes Chromosomes Cancer 2003; 36: 80-89.
38. Srinivasula SM, Ashwell JD. IAPs: what's in a name? Mol Cell 2008; 30: 123-135.
39. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNFrelated apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59: 2747-2753.
40. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000; 60: 553-559.
41. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 2001; 61: 1314-1319.
42. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174: 6477-6489.
43. McDermott SP, Eppert K, Lechman ER, Doedens M, Dick JE. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood 2010; 116: 193-200.
44. Notta F, Doulatov S, Dick JE. Engraftment of human hematopoietic stem cells is more efficient in female NOD/SCID/IL-2Rgc-null recipients. Blood 2010; 115: 3704-3707.
45. Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994; 84: 1243-1248.
46. Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, Imai Y et al. Evi-1 is a transcriptional target of MLL oncoproteins in hematopoietic stem cells. Blood 2010; 117: 6304-6314.
47. Modlich U, Schambach A, Brugman MH, Wicke DC, Knoess S, Li Z et al. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia 2008; 22: 1519-1528.
48. Chiu PP, Jiang H, Dick JE. Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. Blood 2010; 116: 5268-5279.
49. Bonnet D. Humanized model to study leukemic stem cells. Methods Mol Biol 2009; 538: 247-262.
50. Morisot S, Wayne AS, Bohana-Kashtan O, Kaplan IM, Gocke CD, Hildreth R et al. High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. Leukemia 2010; 24: 1859-1866.
51. Meyer LH, Eckhoff SM, Queudeville M, Kraus JM, Giordan M, Stursberg J et al. Early relapse in all is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. Cancer Cell 2011; 19: 206-217.
52. Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, Ogawa S et al. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 2000; 19: 2958-2968.
53. Liu Y, Chen L, Ko TC, Fields AP, Thompson EA. Evi1 is a survival factor which conveys resistance to both TGFbeta-and taxol-mediated cell death via PI3K/AKT. Oncogene 2006; 25: 3565-3575.
54. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y Nitta E et al. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 2011; 117: 3617-3628.
55. Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A. Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer. Gynecol Oncol 2010; 118: 189-195.
56. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006; 12: 440-450.
57. Pradhan AK, Mohapatra AD, Nayak KB, Chakraborty S. Acetylation of the proto-oncogene EVI1 abrogates Bcl-xL promoter binding and induces apoptosis. PLoS One 2011; 6: e25370.
58. Shackelford D, Kenific C, Blusztajn A, Waxman S, Ren R. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Cancer Res 2006; 66: 11360-11369.
59. Raza A, Buonamici S, Lisak L, Tahir S, Li D, Imran M et al. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 2004; 28: 791-803.
60. Zhang Y, Sicot G, Cui X, Vogel M, Wuertzer CA, Lezon-Geyda K et al. Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide. Biochemistry 2011; 50: 10431-10441.